ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.

1994427 citationsJournal Article

Authors

William S. Velasquez · The University of Texas MD Anderson Cancer Center

Peter McLaughlin

S Tucker

Fredrick B. Hagemeister · Lymphoma Research Foundation

F Swan

Maria Alma Rodriguez · Lymphoma Research Foundation

Jorge Romaguera · Lymphoma Research Foundation

Edward Rubenstein

Fernando Cabanillas

Abstract

ESHAP was found to be an active, tolerable chemotherapy regimen for relapsing and refractory lymphoma. Applying a prognostic model based on tumor burden and serum LDH level shows significant differences in survival in this patient population.

Topics & Keywords

Lymphoma Diagnosis and Treatment Lung Cancer Treatments and Mutations Chronic Lymphocytic Leukemia Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 12, Issue 6, pp. 1169-1176

DOI: 10.1200/jco.1994.12.6.1169

Field-Weighted Citation Impact: 9.41